1 reports of this reaction
3.8% of all BRYONIA ALBA ROOT reports
#6 most reported adverse reaction
CHROMATURIA is the #6 most commonly reported adverse reaction for BRYONIA ALBA ROOT, manufactured by Energique, Inc.. There are 1 FDA adverse event reports linking BRYONIA ALBA ROOT to CHROMATURIA. This represents approximately 3.8% of all 26 adverse event reports for this drug.
Patients taking BRYONIA ALBA ROOT who experience chromaturia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CHROMATURIA is moderately reported among BRYONIA ALBA ROOT users, representing a notable but not dominant share of adverse events.
In addition to chromaturia, the following adverse reactions have been reported for BRYONIA ALBA ROOT:
The following drugs have also been linked to chromaturia in FDA adverse event reports:
CHROMATURIA has been reported as an adverse event in 1 FDA reports for BRYONIA ALBA ROOT. This does not prove causation, but indicates an association observed in post-market surveillance data.
CHROMATURIA accounts for approximately 3.8% of all adverse event reports for BRYONIA ALBA ROOT, making it a notable side effect.
If you experience chromaturia while taking BRYONIA ALBA ROOT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.